
Lung Therapeutics Receives Orphan Drug Designation for Empyema Treatment
Lung Therapeutics announced that it received Orphan Drug Designation for LTI-01, an injectable designed for the treatment of loculated pleural effusion.
“Our initial focus is on LTI-01, which is designed to treat empyema and complicated parapneumonic effusions, two complications of pneumonia that can involve fibrinous scarring that inhibits fluid drainage,” said Brian Windsor, PhD, CEO of Lung Therapeutics, in a press release.
LTI-01 is an injectable, fibronolytic drug that promotes healthy fluid drainage by increasing scar removal around the lungs while lessening bleeding and other complications.
“LTI-01 could improve outcomes for thousands of patients a year who become seriously ill with pleural effusions that are difficult to drain, and increasing incidence demands more effective therapy. We believe that LTI-01 will enable patients to avoid surgical treatment and its associated morbidity and cost,” said Steven Idell, MD, PhD, Lung Therapeutics’ founder and chief scientific officer, in a press release.
Lung Therapeutics is also developing LTI-02 for the treatment of acute lung injury and LTI-03 for idiopathic pulmonary fibrosis (IPF). In October 2014, FDA approved the first two IPF treatments,
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.